Table I.
Characteristics of study population
| Osteosarcoma Survivors* (N=24)
|
||
|---|---|---|
| N | (%) | |
| Gender | ||
| Male | 13 | (54.2) |
| Female | 11 | (45.8) |
| Median age in years (range) | ||
| At diagnosis | 18 | (9–32) |
| At survey | 36.5 | (20–56) |
| Time from diagnosis | 14.2 | (6–42) |
| Treatment (not exclusive) | ||
| Chemotherapy | ||
| Doxorubicin (Adriamycin) | 23 | (95.8) |
| Cisplatin | 14 | (58.3) |
| Carboplatin | 3 | (12.5) |
| Methotrexate - IV | 22 | (91.7) |
| Ifosfamide | 14 | (58.3) |
| Cyclophosphamide - IV | 6 | (25.0) |
| VP 16 (Etoposide) - IV | 3 | (12.5) |
| Bleomycin | 5 | (20.8) |
| Mitomycin C | 1 | 4.2 |
| Radiation | 2 | (8.3) |
| Smoke | ||
| Yes | 6 | (25.0) |
| No | 15 | (62.5) |
| Not reported | 3 | (12.5) |
| Median | Range | |
| BMI in kilograms per m2 | 27 | (22–52) |
| Heart rate in beats per minute | 73 | (60–104) |
| Systolic BP in mmHg | 120 | (98–140) |
| Diastolic BP in mmHg | 79 | (52–95) |
*
all participating survivors were Caucasian